Aurion Biotech: Treating endothelial disease with one donor

,

Edward Holland, MD, discusses Aurion Biotech's investigation of an injectable technique where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease.

Edward Holland, MD, chief medical advisor for Aurion Biotech, discusses the company's investigation of injectable endothelial cells, where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease as well as other forms of corneal edema.

See more ASCRS coverage

Related Content:

ConferencesVideosCornea
Deep learning for detection of keratoconus and prediction of CXL efficacy
Evaluating dexamethasone intraocular suspension 9% post-cataract surgery
DED results in imbalance of neuropeptides, neurotrophins in the cornea and trigeminal ganglion